MUC1 immunotherapy.
The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.
Beatson
Richard E
RE
Breast Cancer Biology Group, King's College London, Guy's Hospital, London SE1 9RT, UK.
Taylor-Papadimitriou
Joyce
J
Burchell
Joy M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D006031:Glycosylation; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D018396:Mucin-1 / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D018396:Mucin-1; C469215:pemtumomab